These suggested that HECTD3, PSMB10, UBD, UBE2C, and UBE2S might also affect the efficacy of neoadjuvant chemotherapy in breast cancer through the ubiquitin proteasome pathway. This evidence concerns the gene PSMB10 and breast carcinoma.